Characterization of immune checkpoint inhibitor-related cardiotoxicity in lung cancer patients from a rural setting

Total Number of Patients (

Age (years ± SD)

Gender


Ethnicity

Vidant Medical Center/East Carolina University, Greenville, North Carolina

INTRODUCTION

- Immune checkpoint inhibitor (ICI)-related cardiotoxicities (iRCs) are rare. However, recent literature have described major adverse cardiac events (MACE) such as myocarditis, pericardial disorders, cardiomyopathies and dysrhythmias as potential fatal adverse effects in patients receiving ICIs¹.
- The cardiotoxic profile of ICIs is not well defined. Our study aimed to characterize iRCs in lung cancer patients of a rural population at a tertiary care center.

METHODS



Melissa Y.Y. Moey, Anna N. Tomdio, Justin D. McCallen, Lauren Vaughan, Abdul R. Naqash, Cynthia Cherry, Blase A. Carabello and Paul R. Walker

Table 1. Demographics and baseline characteristics of control and patients with ICI-related cardiotoxicities (iRC).

elated cardiotoxicities (IRC).					
	No MACE	MACE	p value		
atients (n, %)	174 (88%)	23 (11%)			
	64.3 ± 0.79	68.71 ± 1.8	0.064		
Male (n, %)	99 (57%)	15 (65%)	0.456		
Female (n,%)	74 (43%)	8 (35%)			
D look (p. 0)		E (010/)	0 100		
Black $(n, \%)$	66 (38%)	5 (21%)	0.108		
White (n, %)	107 (62%)	18 (78%)			
			0 500		
NSCLC (n, %)	158 (91%)	20 (87%)	0.509		
SCLC (n, %)	15 (9%)	3 (13%)			
nt Inhibitor					
volumab (n, %)	119 (68%)	19 (83%)	0.17		
lizumab (n, %)	44 (25%)	4 (17%)	0.41		
zumab (n, 0%)	11 (6%)	0 (0%)	0.41		
ару					
merase (n, %)	66 (38%)	9 (39%)			
i-VEGF (n, %)	13 (7%)	0 (0%)			
agents, (n, %)	139 (80%	21 (91%)			
tabolites (n, %	68 (40%)	11 (48%)			
Taxane (n, %)	11 (6%)	6 (26%)			
ory					
DM	44 (25%)	7 (30%)	0.61		
HTN	111 (64%)	12 (52%)	0.28		
HLD	56 (32%)	4 (17%)	0.14		
AF	15 (9%)	3 (13%)	0.48		
CKD	9 (5%)	1 (4%)	0.86		
CAD	27 (16%)	8 (35%)	0.02		
Steroids	66 (38%)	18 (78%)	< 0.01		
BB	52 (30%)	15 (65%)	< 0.01		
CCB	34 (20%)	4 (17%)	0.80		
Diuretics	46 (26%)	13 (56%)	0.99		
ACE-I/ARB	41 (24%)	5 (22%)	0.84		
Statins	58 (33%)	12 (52%)	0.076		

Abbreviations: ACE-I: angiotensin converting enzyme inhibitors, AF: atrial fibrillation, ARB: angiotensin receptor blocker, BB: beta-blockers, CCB: calcium channel blockers, CKD: chronic kidney disease, DM: diabetes mellitus, iRC: immunerelated cardiotoxicity, HLD: hyperlipidemia, HTN: hypertension, NSCLC: non-small cell lung cancer, SCLC: small cell lung

Table 2. Comparison of laboratory values in lung cancer patients with no MACE (174) versus with a MACE (n=23)

	No MACE	M
Baseline Laboratory Values		
WBC, K/uL	8.86 ± 5.1	8.92
Hemoglobin, g/dl	11.9 ± 7.4	10.6
Hematocrit, %	35.9 ± 15	32.5
Platelets, K/uL	282 ± 117	239
Creatinine, mg/dl	1.06 ± 0.9	0.91
Neutrophil:lymphocyte ratio (NLR)	8.1 ± 9.0	10.9
CRP, mg/l	37.5 ± 48.1	42.1
Troponin, ng/ml	0.02 ± 0.01	0.03

Table 3. Comparison of laboratory values, ejection fraction, PR interval and QTc interval at baseline and at the time of suspected MACE (n=23)

	Baseline	IV
Laboratory Values		
CRP, mg/l	35 ± 4.1	99
NLR	7.7 ± 0.54	20.7
Troponin I (ng/mL)	0.03 ± 0.01	0.98
Echocardiogram		
Ejection Fraction (%)	50.5 ± 16.2	46.2
		Δ 4.2
Electrocardiogram		
PR Interval (ms)	171.1 ± 29.9	155.
		Δ -19
QTc Interval (ms)	442.4 ± 37.9	466.
		Δ 26.

DISCUSSION


- the time of suspected iRC, suggesting its utility in diagnosing iRC.
- echocardiographic findings), diagnostic work up and surveillance are warranted.

ACKNOWLEDGEMENTS REFERENCES

I would like to thank the organizers of the 2022 Distinction Day for this opportunity. Additionally, I wish to thank Dr. Johanna Hannan and Dr. Kori Brewer for leading the RDT. Finally, I wish to thank Dr. Li Yang and Mona Marie for their additional support in my research throughout medical school.

1. Lvon AR. Yousaf N, Battisti NML et al. Lancet Oncol 19(9):e4470e458, 2018 The primary author and study authors 2. Varricchi G, Galdiero MR, Tocchetti. Circulation 136:1989-1999, 2017 have no disclosures to declare 3. Lalani AA, Xie W, Martini DJ et al., J Immunother Cancer 6(1):5, 2018 4. Zer A, Sung MR, Walia P et al., Clin Lung Cancer 19:426-434, 2018 5. Bhat T, Teli S, Rijal J et al. Expert Rev Cardiovasc Ther 11:55-9, 2013 6. CTCAE. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm





iRCs are rare though can manifest as a spectrum of cardiotoxicities^{1,2}. Majority of these toxicities appear to be grade 3 toxicities (severe undesirable adverse reaction requiring hospitalization or invasive intervention)⁶.

Elevated NLR is an inflammatory marker that has been associated with poor prognosis in cancer^{3,4} as well as mortality in cardiovascular disease⁵. We demonstrate an increased NLR in correlation with an elevated CRP during

iRCs may be underrepresented in clinical trials and further studies describing this syndrome (ECG and

Larger datasets to identify potential predictors that may guide optimal management of these events are encouraged. DISCLOSURES